Rift widens over hep C meds PBS listing delay

Hepatitis Australia (HA) was last week on track to have more than 1000 signatures on a petition calling for Health Minister Tanya Plibersek to urge Cabinet to list new hepatitis C medications boceprevir and telaprevir – which substantially increase cure rates and are subsidised in Europe and Canada – on the PBS this month.

Both treatments, which would cost $50,000 per patient unsubsidised, were recently approved by the PBAC, but HA has complained of a “hold-up” in listing the products, which would only be used in urgent cases due to serious potential side